StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) stock

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)

Close on Nov 17, 2026Market cap $4.87MP/E –Yield –

BioLineRx operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -$10.29M. The highest annual figure on record is -$10.29M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$10.29M–
FY2024Dec 31, 2024-$20.41M–
FY2023Dec 31, 2023-$49.69M–
FY2022Dec 31, 2022-$29.16M–
FY2021Dec 31, 2021-$24.78M–
FY2020Dec 31, 2020-$22.93M–
FY2019Dec 31, 2019-$28.11M–
FY2018Dec 31, 2018-$25.61M–
FY2017Dec 31, 2017-$25.24M–
FY2016Dec 31, 2016-$16.51M–
FY2015Dec 31, 2015-$16.20M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.57M–
Q2 FY2025Jun 30, 2025-$2.30M–
Q2 FY2024Jun 30, 2024-$5.77M–
Q2 FY2023Jun 30, 2023-$9.92M–
Q2 FY2022Jun 30, 2022-$7.60M–
Q2 FY2021Jun 30, 2021-$6.51M–
Q2 FY2020Jun 30, 2020-$5.57M–
Q2 FY2019Jun 30, 2019-$6.48M–
Q2 FY2018Jun 30, 2018-$5.73M–
Q2 FY2017Jun 30, 2017-$5.19M–

More BioLineRx figures

See a number that looks wrong?